336 related articles for article (PubMed ID: 28704384)
21. Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer.
Lin Y; Li T; Liang J; Li X; Qiu L; Wang S; Chen Y; Kang Z; Li F
Clin Nucl Med; 2011 Dec; 36(12):1102-5. PubMed ID: 22064080
[TBL] [Abstract][Full Text] [Related]
22. Impact factors for the outcome of the first
Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
[TBL] [Abstract][Full Text] [Related]
23. PRE-ABLATION THYROGLOBULIN AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER.
Livhits MJ; Pasternak JD; Xiong M; Li N; Gosnell JE; Yeh MW; Chiu HK
Endocr Pract; 2016 Nov; 22(11):1259-1266. PubMed ID: 27482611
[TBL] [Abstract][Full Text] [Related]
24. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
[TBL] [Abstract][Full Text] [Related]
25. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
26. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.
Prpic M; Kruljac I; Kust D; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
Endocrine; 2016 Jun; 52(3):602-8. PubMed ID: 26732041
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of postoperative anti-thyroglobulin antibody in patients with differentiated thyroid cancer.
Zhao Y; Mu Z; Liang D; Zhang T; Zhang X; Sun D; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2024; 15():1354426. PubMed ID: 38721144
[TBL] [Abstract][Full Text] [Related]
28. Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status.
Schubert L; Mbekwe-Yepnang AM; Wassermann J; Braik-Djellas Y; Jaffrelot L; Pani F; Deniziaut G; Lussey-Lepoutre C; Chereau N; Leenhardt L; Bernier MO; Buffet C
J Endocrinol Invest; 2024 Jun; 47(6):1573-1581. PubMed ID: 38578580
[TBL] [Abstract][Full Text] [Related]
29. Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer.
Wang TS; Evans DB; Fareau GG; Carroll T; Yen TW
Ann Surg Oncol; 2012 Dec; 19(13):4217-22. PubMed ID: 23010732
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of the value of first thyroglobulin determination in the diagnostics of metastases immediately following differentiated thyroid carcinoma surgery.
Makarewicz J; Adamczewski Z; Rutkowski A; Mikosiński S; Knapska-Kucharska M; Gonerska-Szadkowska A; Oszukowska L; Karwowska A; Lewiński A
Endokrynol Pol; 2006; 57(4):370-3. PubMed ID: 17006838
[TBL] [Abstract][Full Text] [Related]
31. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
32. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
33. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
34. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
Schlumberger M; Hitzel A; Toubert ME; Corone C; Troalen F; Schlageter MH; Claustrat F; Koscielny S; Taieb D; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Torlontano M; Tenenbaum F; Bardet S; Bussière F; Girard JJ; Morel O; Schneegans O; Schlienger JL; Prost A; So D; Archambeaud F; Ricard M; Benhamou E
J Clin Endocrinol Metab; 2007 Jul; 92(7):2487-95. PubMed ID: 17426102
[TBL] [Abstract][Full Text] [Related]
35. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.
Padovani RP; Robenshtok E; Brokhin M; Tuttle RM
Thyroid; 2012 Aug; 22(8):778-83. PubMed ID: 22780333
[TBL] [Abstract][Full Text] [Related]
36. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
[TBL] [Abstract][Full Text] [Related]
37. Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
Barres B; Kelly A; Kwiatkowski F; Batisse-Lignier M; Fouilhoux G; Aubert B; Dutheil F; Tauveron I; Cachin F; Maqdasy S
J Clin Endocrinol Metab; 2019 Aug; 104(8):3462-3472. PubMed ID: 30785995
[TBL] [Abstract][Full Text] [Related]
38. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
Brassard M; Borget I; Edet-Sanson A; Giraudet AL; Mundler O; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Toubert ME; Torlontano M; Benhamou E; Schlumberger M;
J Clin Endocrinol Metab; 2011 May; 96(5):1352-9. PubMed ID: 21389143
[TBL] [Abstract][Full Text] [Related]
40. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
